Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262560 · ClinicalTrials.gov registry record · Phase 2
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT01262560 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 163 participants.
The verdict
NCT01262560, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain. PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation therapy for lung cancer.
Interventions
- DRUG Manuka honey in liquid form
- DRUG Manuka honey in lozenge form
- DRUG Standard supportive care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262560
The ClinicalTrials.gov registry entry for NCT01262560 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Manuka honey in liquid form is the first listed.
NCT01262560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01262560 about?
NCT01262560 is a clinical study titled "Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer". RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain. PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how...
What is the current status of trial NCT01262560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2012-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01262560?
The interventions under investigation include: Manuka honey in liquid form (DRUG), Manuka honey in lozenge form (DRUG), Standard supportive care (DRUG).
Who is sponsoring clinical trial NCT01262560?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.